No results for ‘’
Biogen Pharmachem Industries Ltd
₹0.27
(0%)
Fri, 18 Sept 2026, 04:39 am
Finance
Investment Banks/Brokers
24.5KBiogen Pharmachem Industries Enterprise Value (EV)
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84.29 | 35.81 | 0 |
| Price to book ratio | 0 | 0 | 0.32 | 0.09 | 0.42 | 0.26 | 0.22 | 0.32 | 0.22 | 0.24 | 0.23 | 0.23 | 0.28 | 0.22 | 0.25 | 1.69 | 0.71 | 1.22 | 0.68 |
| Price to sales ratio | 0 | 0 | 0.01 | 1.80 | 62.99 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 15.80 | 0 | 947.16 | 42.13 | 42.18 | 29.05 | 74.73 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0.10 | 55.06 | 0 | 0.48 | 0 | 0 | 171.52 | 0 | 3.47 | 65.34 | 22.59 | 35.57 | 0 |
| Enterprise value | 0 | 0 | 2.11Cr | 3.35Cr | -11.91Cr | 1.59Cr | -41.85Cr | 13.63Cr | -12.53Cr | -5.73Cr | -2.38Cr | 12.39Cr | 15.64Cr | 12.7Cr | 13.7Cr | 91.28Cr | 38.38Cr | 69.16Cr | 60.63Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | -449.99 | 646.61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84.23 | 35.82 | 0 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0.07 | 0.04 | 0.94 | 0.16 | 0.10 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | -2.20 | -49.20 | -0.03 | -0.31 | -0.15 | -0.22 | -0.21 | -0.22 | -0.05 | -0.20 | -11.40 | -0.01 | -0.21 | -2.92 | -0.02 | 0.84 | 3.48 | -0.39 |
Biogen Pharmachem Industries Ltd Enterprise Value
The Biogen Pharmachem Industries Ltd Enterprise Value is a key financial metric used by investors to evaluate Biogen Pharmachem Industries Ltd's valuation, profitability, and overall financial performance. Tracking the Biogen Pharmachem Industries Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Biogen Pharmachem Industries Ltd (NSE: , BSE: 531752) is currently trading at ₹0.27, with a market capitalization of ₹28.43Cr. As a leading company in the Finance sector and Investment banks/Brokers industry, monitoring the Biogen Pharmachem Industries Ltd Enterprise Value is essential for fundamental analysis.
Biogen Pharmachem Industries Ltd Enterprise Value Current Value
The current Biogen Pharmachem Industries Ltd Enterprise Value stands at 60.63Cr.
The Biogen Pharmachem Industries Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Biogen Pharmachem Industries Ltd Enterprise Value Historical Trend
The Biogen Pharmachem Industries Ltd Enterprise Value has shown the following historical trend:
- 2024: 60.63Cr
- 2023: 69.16Cr
- 2022: 38.38Cr
- 2021: 91.28Cr
- 2020: 13.7Cr
The decline in Biogen Pharmachem Industries Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Biogen Pharmachem Industries Ltd Enterprise Value Indicates for Investors
The Biogen Pharmachem Industries Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Biogen Pharmachem Industries Ltd.
Biogen Pharmachem Industries Ltd Enterprise Value Analysis Summary
The Biogen Pharmachem Industries Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Biogen Pharmachem Industries Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Biogen Pharmachem Industries Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.